Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H23N3O2 |
Molecular Weight | 277.362 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1
InChI
InChIKey=KEECCEWTUVWFCV-UHFFFAOYSA-N
InChI=1S/C15H23N3O2/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19)
Molecular Formula | C15H23N3O2 |
Molecular Weight | 277.362 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Acecainide (N-acetylprocainamide), the N-acetylated metabolite of procainamide, is a Class III antiarrhythmic agent. Acecainide exerts cardiac anticholinergic effect. It elicits smooth muscle relaxation mainly through the activation of plasma membrane K+ channels. Acecainide markedly reduced premature ventricular beats and prevented induction of ventricular tachycardia. Acecainide appears to offer advantages over procainamide, particularly with respect to the reduced formation of antinuclear antibodies. Acecainide development has been discontinued.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. | 2002 Jul |
|
Massive cell vacuolization induced by organic amines such as procainamide. | 2004 Jul |
|
Class I antiarrhythmics inhibit Na+ absorption and Cl- secretion in rabbit descending colon epithelium. | 2005 Jun |
|
High-throughput solution-based medicinal library screening against human serum albumin. | 2005 Mar 1 |
|
St. John's wort does not interfere with therapeutic drug monitoring of 12 commonly monitored drugs using immunoassays. | 2006 |
|
Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. | 2006 Jan |
|
Simultaneous determination of procaine and para-aminobenzoic acid by LC-MS/MS method. | 2007 Mar 1 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:44:01 GMT 2023
by
admin
on
Sat Dec 16 07:44:01 GMT 2023
|
Record UNII |
910Q707V6F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
35989
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
||
|
NCI_THESAURUS |
C47793
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
||
|
FDA ORPHAN DRUG |
99196
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
||
|
NCI_THESAURUS |
C93038
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m1291
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000081770
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | |||
|
D000120
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | |||
|
60728
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | |||
|
N-ACETYLPROCAINAMIDE
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | |||
|
4342
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | |||
|
4409
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | |||
|
910Q707V6F
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL1097
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | |||
|
C75125
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | |||
|
SUB07372MIG
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | |||
|
32795-44-1
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY | |||
|
DTXSID6048414
Created by
admin on Sat Dec 16 07:44:01 GMT 2023 , Edited by admin on Sat Dec 16 07:44:01 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
|
||
|
PARENT -> METABOLITE |
Percent of dose excreted in urine as metabolite.
AMOUNT EXCRETED
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |